Claims for Patent: 8,168,584

Summary for Patent: 8,168,584

Title:	Methods of treating age-related macular degeneration by compstatin and analogs thereof
Abstract:	The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.
Inventor(s):	Pascal Deschatelets, Paul Olson, Cedric Francois
Assignee:	Apellis Pharmaceuticals Inc
Application Number:	US11/544,389
Patent Claims:	1. A method of treating age-related macular degeneration (ARMD), comprising the step of: administering a composition comprising an effective amount of a compstatin analog to a subject suffering from ARMD, wherein the compstatin analog is a compound that comprises a cyclic peptide comprising a cyclic portion 11 amino acids in length having a core sequence of X′aa-Gln-Asp-Xaa-Gly-X″aa (SEQ ID NO: 4), where X′aa and Xaa are each independently selected from Trp and analogs of Trp and X″aa is selected from Ala, single methyl unbranched amino acids, Phe, Trp, and analogs of Trp, and wherein, when the core sequence is aligned with the sequence of compstatin (i) X′aa corresponds to position 4 of compstatin; (ii) X″aa corresponds to position 9 of compstatin; and (iii) the peptide is cyclized via a bond between amino acids at positions that correspond to position 2 and position 12 of compstatin. 2. The method of claim 1, wherein the compstatin analog inhibits the classical complement pathway. 3. The method of claim 1, wherein the compstatin analog inhibits the alternate complement pathway. 4. The method of claim 1, wherein the compstatin analog inhibits both the classical and alternate pathways. 5. The method of claim 1, wherein the peptide has a sequence of X′aa1-X′aa2-X′aa3-X′aa-Gln-Asp-Xaa-Gly-X″aa-X″aa2-X″aa3-X″aa4-X″aa5 (SEQ ID NO: 5), and X′aa1, X′aa2, X′aa3, X″aa2, X″aa3-X″aa4, and X″aa5 are identical to the amino acids at the corresponding positions in compstatin. 6. The method of claim 1, wherein the compstatin analog is a compound that comprises a cyclic peptide having a sequence of X′aa1-X′aa2-X′aa3-X′aa4-Gln-Asp-Xaa-Gly-X″aa1-X″aa2-X″aa3-X″aa4-X″aa-5 (SEQ ID NO: 5), where X′aa4 and Xaa are selected from Trp and analogs of Trp, wherein X′aa1, X′aa2, X′aa3, X″aa1, X″aa2, X″aa3, X″aa4, and X″aa5 are independently selected from among amino acids and amino acid analogs, and the peptide is cyclized via a bond between X′aa2 and X″aa4. 7. The method of claim 6, wherein X′aa1, X′aa2, X′aa3, X″aa2, X″aa3, X″aa4, and X″aa5 are identical to the amino acids at the corresponding positions in compstatin and X″aa1 is Ala or a single methyl unbranched amino acid. 8. The method of claim 1, wherein the compstatin analog is a compound that comprises a cyclic peptide having a sequence: Xaa1-Cys-Val-Xaa2-Gln-Asp-Xaa2*-Gly-Xaa3-His-Arg-Cys-Xaa4 (SEQ ID NO: 6); wherein: Xaa1 is Ile, Val, Leu, B1-Ile, B1-Val, B1-Leu or a dipeptide comprising Gly-Ile, or B1-Gly-Ile, and B1 represents a first blocking moiety; Xaa2 and Xaa2* are independently selected from Trp and analogs of Trp; Xaa3 is His, Ala or an analog of Ala, Phe, Trp, or an analog of Trp; Xaa4 is L-Thr, D-Thr, Ile, Val, Gly, a dipeptide selected from Thr-Ala and Thr-Asn, or a tripeptide comprising Thr-Ala-Asn, wherein a carboxy terminal —OH of any of the L-Thr, D-Thr, Ile, Val, Gly, Ala, or Asn optionally is replaced by a second blocking moiety B2; and the two Cys residues are joined by a disulfide bond. 9. The method of claim 1, wherein the peptide is acetylated at the N-terminus, amidated at the C-terminus, or both acetylated at the N-terminus and amidated at the C-terminus. 10. The method of claim 8, wherein Xaa1 is Ile, Val, Leu, Ac-Ile, Ac-Val, Ac-Leu or a dipeptide comprising Gly-Ile or Ac-Gly-Ile; Xaa2 and Xaa2* are independently selected from Trp and analogs of Trp; Xaa3 is His, Ala or an analog of Ala, Phe, Trp, or an analog of Trp; Xaa4 is L-Thr, D-Thr, Ile, Val, Gly, a dipeptide selected from Thr-Ala and Thr-Asn, or a tripeptide comprising Thr-Ala-Asn, wherein a carboxy terminal —OH of any of the L-Thr, D-Thr, Ile, Val, Gly, Ala, or Asn optionally is replaced by —NH2. 11. The method of claim 8, wherein Xaa2 is an analog of Trp having increased hydrophobic character relative to Trp. 12. The method of claim 8, wherein Xaa2 is an analog of Trp comprising a substituted or unsubstituted bicyclic aromatic ring component or two or more substituted or unsubstituted monocyclic aromatic ring components. 13. The method of claim 8, wherein Xaa2* is an analog of Trp having an electronegative substituent on the indole ring and not having increased hydrophobic character relative to Trp. 14. The method of claim 1, wherein the compstatin analog has a sequence selected from the group consisting of: SEQ ID NOs: 11-32. 15. The method of claim 1, wherein the compstatin analog has a sequence selected from the group consisting of: SEQ ID NOs: 14, 21, 28, 29, and 32. 16. The method of claim 1, wherein the compstatin analog has a sequence selected from the group consisting of: SEQ ID NOs: 30 and 31. 17. The method of claim 1, wherein the compstatin analog is a compound that comprises a cyclic peptide having a sequence of X′aa1-X′aa2-X′aa3-X′aa4-Gln-Asp-Xaa-Gly-X″aa1-X″aa2-X″aa3-X″aa4-X″aa-5 (SEQ ID NO: 5), where X′aa4 and Xaa are selected from Trp and analogs of Trp, wherein X′aa1, X′aa2, X′aa3, X″aa1, X″aa2, X″aa3, X″aa4, and X″aa5 are independently selected from among amino acids and amino acid analogs, X′aa2 and X″aa4 are not Cys, and the peptide is cyclized via a bond between X′aa2 and X″aa4. 18. The method of claim 17, wherein X′aa1, X′aa3, X″aa2, X″aa3, and X″aa5 are identical to the amino acids at the corresponding positions in compstatin and X″aa1 is Ala or a single methyl unbranched amino acid. 19. The method of claim 17, wherein the bond is an amide bond, wherein one of X′aa2 and X″aa4 is an amino acid or amino acid analog having a side chain that comprises a primary or secondary amine, the other one of X′aa2 and X″aa4 is an amino acid or amino acid analog having a side chain that comprises a carboxylic acid group, and the bond is an amide bond. 20. The method of claim 1, wherein the composition is administered intravitreally. 21. The method of claim 1, wherein the composition is administered intravitreally in an ocular insert. 22. The method of claim 1, wherein the composition is administered intravitreally in an ocular insert in an amount between 100 μg and 500 μg. 23. The method of claim 1, wherein the composition is administered intravitreally in a sustained release formulation in an amount between 100 μg and 10,000 μg. 24. The method of claim 1, wherein the composition is administered intravitreally in a sustained-release formulation comprising a plurality of microparticles or nanoparticles collectively comprising between 100 μg and 10,000 μg of the compstatin analog. 25. The method of claim 1, wherein the composition is locally administered to the eye or in the vicinity of the eye. 26. The method of claim 25 wherein the composition is locally administered as a liquid. 27. The method of claim 1, wherein the composition is locally administered in an ocular or periocular implant or insert. 28. The method of claim 1, wherein the subject is suffering from ARMD and is at risk of or suffering from retinal angiomatous proliferation (RAP). 29. The method of claim 1, wherein the subject is suffering from ARMD and is at risk of or suffering from choroidal neovascularization (CNV). 30. The method of claim 1, wherein the subject is suffering from ARMD and is at risk of or suffering from retinal neovascularization (RNV). 31. The method of claim 1, wherein the subject has been identified as having one or more genetic polymorphisms that increases the risk of ARMD. 32. The method of claim 1, further comprising determining whether the subject has a genetic polymorphism that increases the risk of ARMD. 33. The method of claim 1, further comprising administering an effective amount of an angiogenesis inhibitor up to 4 weeks prior to administering the compstatin analog. 34. A method of treating an eye disorder associated with or caused at least in part by complement activation, the method comprising the step of administering an effective amount of a compstatin analog to a subject suffering from the eye disorder, wherein the compstatin analog is a compound that comprises a cyclic peptide comprising a cyclic portion 11 amino acids in length having a core sequence of X′aa-Gln-Asp-Xaa-Gly-X″aa (SEQ ID NO: 4), where X′aa and Xaa are each independently selected from Trp and analogs of Trp and X″aa is selected from Ala, single methyl unbranched amino acids, Phe, Trp, and analogs of Trp, and wherein, when the core sequence is aligned with the sequence of compstatin (i) X′aa corresponds to position 4 of compstatin; (ii) X″aa corresponds to position 9 of compstatin; and (iii) the peptide is cyclized via a bond between amino acids at positions that correspond to position 2 and position 12 of compstatin. 35. A method of treating an eye disorder characterized in that a polymorphism in, or in linkage disequilibrium with, a gene that encodes a complement component is associated with an increased risk of the disorder, the method comprising the step of administering an effective amount of a compstatin analog to a subject suffering from the eye disorder, wherein the compstatin analog is a compound that comprises a cyclic peptide comprising a cyclic portion 11 amino acids in length having a core sequence of X′aa-Gln-Asp-Xaa-Gly-X″aa (SEQ ID NO: 4), where X′aa and Xaa are each independently selected from Trp and analogs of Trp and X″aa is selected from Ala, single methyl unbranched amino acids, Phe, Trp, and analogs of Trp, and wherein, when the core sequence is aligned with the sequence of compstatin (i) X′aa corresponds to position 4 of compstatin; (ii) X″aa corresponds to position 9 of compstatin; and (iii) the peptide is cyclized via a bond between amino acids at positions that correspond to position 2 and position 12 of compstatin. 36. A method of inhibiting neovascularization in the eye of a subject suffering from age-related macular degeneration, comprising the step of: administering a composition comprising an effective amount of a compstatin analog to or in close proximity to the posterior segment of the subject's eye, wherein the compstatin analog is a compound that comprises a cyclic peptide comprising a cyclic portion 11 amino acids in length having a core sequence of X′aa-Gln-Asp-Xaa-Gly-X″aa (SEQ ID NO: 4), where X′aa and Xaa are each independently selected from Trp and analogs of Trp and X″aa is selected from Ala, single methyl unbranched amino acids, Phe, Trp, and analogs of Trp, and wherein, when the core sequence is aligned with the sequence of compstatin (i) X′aa corresponds to position 4 of compstatin; (ii) X″aa corresponds to position 9 of compstatin; and (iii) the peptide is cyclized via a bond between amino acids at positions that correspond to position 2 and position 12 of compstatin. 37. The method of claim 36, wherein the compstatin analog inhibits the classical complement pathway. 38. The method of claim 36, wherein the compstatin analog inhibits the alternate complement pathway. 39. The method of claim 36, wherein the compstatin analog inhibits both the classical and alternate pathways. 40. The method of claim 36, wherein the composition is administered as a liquid. 41. The method of claim 36, wherein the composition is administered by a method selected from the group consisting of: retrobulbar injection, peribulbar injection, sub-Tenon injection, subconjunctival injection, and intravitreal injection. 42. The method of claim 36, wherein the composition is administered as an ointment or gel. 43. The method of claim 36, wherein the composition is administered in an ocular or periocular implant or insert. 44. The method of claim 36, wherein the composition is administered as a solution that forms a gel after introduction into the body. 45. The method of claim 36, wherein the subject is suffering from ARMD and is at risk of or suffering from CNV. 46. The method of claim 36, wherein the subject suffering from ARMD is at risk of or suffering from RAP. 47. The method of claim 36, wherein the subject suffering from ARMD is at risk of or suffering from retinal neovascularization (RNV). 48. The method of claim 36, wherein the subject has not developed detectable CNV and the composition delays the development of CNV. 49. The method of claim 36, wherein the subject has developed detectable CNV and the composition slows the rate of progression of CNV or causes regression of CNV. 50. The method of claim 36, wherein a composition comprising the compstatin analog is administered to the subject multiple times. 51. The method of claim 26, wherein the composition is administered by intravitreal injection. 52. The method of claim 1, wherein the amino acids at positions that correspond to position 2 and position 12 of compstatin are cysteines. 53. The method of claim 1, wherein the cyclic peptide further comprises three additional amino acids X′aa1, X′aa2, and X′aa3 located immediately N-terminus to the core sequence in that order and an additional four amino acids X″aa2, X″aa3, X″aa4, and X″aa5 located immediately C-terminus to the core sequence in that order, wherein X′aa1, X′aa2, X′aa3, X″aa2, X″aa3, X″aa4, and X″aa5 are identical to the amino acids at the corresponding positions in compstatin. 54. The method of claim 53, wherein the peptide is acetylated at the N-terminus, amidated at the C-terminus, or both acetylated at the N-terminus and amidated at the C-terminus. 55. The method of claim 53, wherein X′aa is 1-methyl tryptophan and X″aa is Ala. 56. The method of claim 55, wherein the peptide is acetylated at the N-terminus, amidated at the C-terminus, or both acetylated at the N-terminus and amidated at the C-terminus. 57. The method of claim 55, wherein Xaa is Trp. 58. The method of claim 55, wherein Xaa is 5-fluoro-Tryptophan.